Chapter 6 176 Table 6.1. Demographic and clinical characteristics at the baseline measurement and 3 month follow up. Transmasculine participants (n=38) Transfeminine participants (n=35) Measurement Baseline n=36 3 months n=26 Baseline n=32 3 months n=24 Age median, 25th and 75th percentile 23 (21 to 25) 22 (20 to 24.8) 26 (23.8 to 29.3) 27 (24 to 33) Center (n, %) Amsterdam UMC 31 (86.1%) 23 (88.4%) 29 (90.6%) 20 (83.3%) UMCG 5 (13.9%) 3 (11.5%) 3 (9.4%) 4 (16.7%) Psychotropic medication use (n, %) Any psychotropic medication 6 (16.7%) 5 (19.2%) 4 (12.5%) 4 (16.7%) Antidepressants 4 (11.1%) 3 (11.5%) 3 (9.4%) 1 (4.2%) Antipsychotics 1 (2.8%) 0 (0%) 0 (0%) 0 (0%) Anxiolytics 0 (0%) 0 (0%) 0 (0%) 0 (0%) Stimulants 2 (5.6%) 2 (8.3%) 2 (6.3%) 2 (8.3%) Mood stabilizers 0 (0%) 0 (0%) 0 (0%) 0 (0%) Testosterone serum level (nmol/L; median, IQR)1. No cycle regulation use (in TM participants) 0.9 (0.8 to 1.2) 16 (9 to 23) 14 (10 to 17) 0.6 (0.4 to 0.8) Cycle regulation use (in TM participants) 0.6 (0.4 to 0.9) 15 (12 to 18) - - Estradiol serum level (pmol/L, median; IQR)1. No cycle regulation use (in TM participants) 193 (135 to 291) 153 (109 to 202) 76 (63 to 90) 280 (177 to 378) Cycle regulation use (in TM participants) 77 (46 to 104) 99 (71 to 166) - - PSQI score median, 25th and 75th percentile 7 (3.5 to 9.5) 5 (4 to 7) 2. * 6 (4 to 7) 5 (3.5 to 7) Mean, SD 6.58 (3.22) 5.52 (2.0) 5.90 (2.62) 5.17 (2.29) ISI score median, 25th and 75th percentile 6 (4.5 to 10) 6 (4 to 7.5) 2. * 5.5 (3 to 9) 5.5 (3 to 10.3) Mean, SD 7.54 (4.85) 5.96 (3.43) 6.31 (4.65) 6.96 (5.05) 1. Reference ranges in cisgender persons: testosterone 9 nmol/L to 30 nmol/L and estradiol 12 pmol/L to 126 pmol/L in cisgender males and testosterone 0.3 to 1.6 nmol/L and 31 pmol/L to 2864 pmol/L in cisgender females (Amsterdam UMC Endocrinologisch Lab, z.d.; Verdonk et al., 2019). According to WPATH SOC 8 guidelines, treatment providers should aim for serum levels associated with users’ gender identity, e.g. transmasculine GAHT users meeting the cis male reference range and transfeminine GAHT users meeting the cis female reference range. 2. Significant change in the PSQI and ISI compared to baseline in the TM group. The PSQI is estimated to reduce by 0.89 points (95% CI: -1.62 to 0.18; p=0.022) and the ISI is estimated to reduce by 1.37 points (95% CI: -2.38 to -0.39, p=0.012).
RkJQdWJsaXNoZXIy MTk4NDMw